

PHA-793887

Chemical Properties


CAS No. : 718630-59-2

Formula: C₁₉H₃₁N₅O₂

Molecular Weight: 361.48

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

| | |
|---------------|--|
| Description | PHA-793887 has been used in trials studying the treatment of Advanced/Metastatic Solid Tumors. |
| Targets(IC50) | Apoptosis,CDK |
| In vitro | PHA-793887, at a dosage of 20 mg/kg, has been demonstrated to be effective in treating transplant tumor models carrying K562 and HL60 cells, primary leukemia dissemination cell models, and high-burden disseminated ALL-2 models in relapsed Philadelphia-positive acute lymphoblastic leukemia patients. Additionally, PHA-793887 (administered at doses ranging from 10-30 mg/kg) exhibits good efficacy in xenograft models of human ovarian A2780, colon HCT-116, and pancreatic BX-PC3 cancers. |
| In vivo | PHA-793887 induces cell cycle arrest and inhibits Rb protein and nuclear phosphorylation at concentrations ranging from 0.2-1 μ M, while also regulating the expression of cyclin E and cdc6. At 5 μ M, it prompts apoptosis. This compound displays cytotoxicity towards leukemia cell lines (including K562, KU812, KCL22, and TOM1) with an IC50 of 0.3-7 μ M, yet it shows no cytotoxic effects on normal, unstimulated peripheral blood mononuclear cells or CD34+ hematopoietic stem cells. PHA-793887 exhibits high activity against leukemia cell lines with an IC50 of <0.1 μ M. Furthermore, PHA-793887 inhibits the proliferation of several tumor cell lines (including A2780, HCT-116, COLO-205, C-433, DU-145, A375, PC3, MCF-7, and BX-PC3) with IC50 values ranging from 88 nM to 3.4 μ M. |
| Kinase Assay | CDK Kinase Assay: The biochemical activity of compounds is determined by incubation with specific enzymes and substrates, followed by quantitation of the phosphorylated product. PHA-793887 (1.5 nM-10 μ M) is incubated for 30-90 min at room temperature in the presence of ATP/ ³³ P- γ -ATP mix, substrate, and the specific enzyme (0.7-100 nM) in a final volume of 30 μ L of kinase buffer, using 96 U bottom plates. After incubation, the reaction is stopped and the phosphorylated substrate is separated from nonincorporated radioactive ATP using SPA beads, Dowex resin, or Multiscreen phosphocellulose filter as follows: (1) For SPA Assays. The reaction is stopped by the addition of 100 μ L of PBS + 32 mM EDTA + 0.1% Triton X-100 + 500 μ M ATP, containing 1 mg of streptavidin-coated SPA beads. After 20 min of incubation for substrate capture, 100 μ L of the reaction mixture is transferred into Optiplate 96-well plates containing 100 μ L of 5 M CsCl, left to stand for 4 hours to allow stratification of beads to the top of the plate, and counted using TopCount to measure substrate-incorporated phosphate. (2) |

A DRUG SCREENING EXPERT

| | |
|---------------|--|
| Kinase Assay | For Dowex Resin Assay. An amount of 150 μ L of resin/formate, pH 3.00, is added to stop the reaction and capture unreacted 32 P- γ -ATP, separating it from the phosphorylated substrate in solution. After 60 min of rest, 50 μ L of supernatant is transferred to Optiplate 96-well plates. After the addition of 150 μ L of Microscint 40, the radioactivity is counted in the TopCount. (3) For Multiscreen Assay. The reaction is stopped with the addition of 10 μ L of EDTA (150 mM). An amount of 100 μ L is transferred to a MultiScreen plate to allow substrate binding to phosphocellulose filter. Plates are then washed three times with 100 μ L of H ₂ PO ₄ (75 mM) filtered by a MultiScreen filtration system, and dried. After the addition of 100 μ L of Microscint 0, radioactivity is counted in the TopCount. IC ₅₀ values are obtained by nonlinear regression analysis. |
| Cell Research | Cells are seeded into 96- or 384-wells plates at final concentration ranging from 1×10^4 to 3×10^4 per cm ² . After 24 hours, cells are treated using serial dilution of PHA-793887. At 72 hours after the treatment, the amount of cells are evaluated using the CellTiter-Glo assay. IC ₅₀ values are calculated using a sigmoidal fit(Only for Reference) |

Solubility Information

| | |
|---------------------|---|
| Solubility | Ethanol: 67 mg/mL (185.35 mM),Sonication is recommended. DMSO: 61.25 mg/mL (169.44 mM),Sonication is recommended. H ₂ O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble) |
| In vivo Formulation | 10% DMSO+90% Saline: 2.5 mg/mL (6.92 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i> |

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|-----------|-----------|
| 1 mM | 2.7664 mL | 13.832 mL | 27.664 mL |
| 5 mM | 0.5533 mL | 2.7664 mL | 5.5328 mL |
| 10 mM | 0.2766 mL | 1.3832 mL | 2.7664 mL |
| 50 mM | 0.0553 mL | 0.2766 mL | 0.5533 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Brasca MG, et al. Bioorg Med Chem, 2010, 18(5), 1844-1853.

Ou J, Li H, Qiu P, et al. CDK9 modulates circadian clock by attenuating REV-ERB α activity. Biochemical and Biophysical Research Communications. 2019 Jun 11;513(4):967-973

Alzani R, et al. Exp Hematol, 2010, 38(4), 259-269.

Pevarello P, et al. J Med Chem, 2004, 47(13), 3367-3380.

Ou J, Li H, Qiu P, et al. CDK9 modulates circadian clock by attenuating REV-ERB α activity[J]. Biochemical and biophysical research communications. 2019 Jun 11;513(4):967-973.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481